Table 4. Clinical trials of immunotherapy for LT.

No. of NCT	PI	Intervention model description	Intervention/treatment	Primary outcomes measures	Secondary outcome measures	Status
LT, liver transplantation; PI, principal investigator; RFS, recurrence-free survival; OS, overall survival; I.V., intravenous; AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; ORR, objective response rate; PFS, progression-free survival; TTP, time to progression; SAE, serious adverse event; GR, graft rejection; NK, nature killer.
NCT05027425	Davendra Sohal et al.	Single-arm, open-label, multicenter clinical trial, phase II	Four months durvalumab plus tremelimumab, after 72 d undergo LT	Cellular rejection rates	1. AEs during treatment, and graft loss and mortality rates2. Radiologic responses via RECIST 1.1 and/or mRECIST3. Pathologic responses via explanted liver assessment4. RFS and OS outcomes based on survival follow-up reporting	Not yet recruiting
NCT03966209	Huang et al.	Single group assignment, open label, phase I	JS001(PD-1 inhibitor) 240 mg I.V. Q3W	1. Serious AEs rate2. Acute graft rejection rate	ORR, PFS, OS	Recruiting
NCT04564313	Wang et al.	Single group assignment, open label, phase I	Camrelizumab (SHR-1210), 200 mg, I.V., Q3W	ORR	OS, PFS, TTP, SAE, GR	Recruiting
NCT01147380	Seigo Nishida et al.	Non-randomized, parallel assignment, open label, phase I	Small dose: inoculation NK cells between 10 and 100 million cellsLarge dose: inoculation cells between 100 and 1,000 million cells	Side effects of cadaveric donor liver NK cell infusion	1. NK cell infusion-related toxicity2. Anti-HCC effect of this treatment3. Anti-HCV effect of this treatment (if applicable)	Completed
NCT02849015	Chen et al.	Randomized, parallel assignment, open label phase I, phase II	Device: CryosurgeryBiological: NK immunotherapy	No. of participants with treatment-related AEs as assessed by CTCAE v4.0 (Time frame: 3 months)	PFS, OS	Completed